Fredrik Schjesvold, Head of Oslo Myeloma Center at Oslo University Hospital, shared a post on LinkedIn:
“Now CAR-T for myeloma is approved also in Sweden, even at first relapse. From before it was already approved in Denmark, at third relapse.
Both other Scandinavian countries have found cilta-cel to be cost-efficient.
More posts featuring Myeloma.